Glioblastoma is an aggressive primary brain tumor that requires coordinated neuro-oncology rather than a single isolated procedure. A German specialist team needs to review the MRI, operative history, neuropathology and molecular findings together with the patient's neurologic condition and prior treatment. Heidelberg and Freiburg both publish multidisciplinary brain-tumor pathways involving neurosurgery, neurology, neuropathology, neuroradiology, radiation oncology and medical oncology, with clinical-trial access for selected patients.
Confirm the diagnosis with modern neuropathology
Brain-tumor classification increasingly uses histology together with molecular and epigenetic information. Heidelberg's neuro-oncology program describes molecular stratification and DNA methylation analysis, while Freiburg notes the growing importance of immunohistochemical and molecular-genetic parameters. For an international second opinion, send the original pathology report and ask whether tissue, blocks or slides need expert re-review.
Newly diagnosed and recurrent glioblastoma are different questions
The German team needs to know whether the request concerns first treatment after diagnosis or disease progression after surgery, radiotherapy and systemic therapy. Current Heidelberg trials separately address newly diagnosed and recurrent glioblastoma, illustrating why previous treatment and timing of progression materially change the available options.
Surgery or biopsy is only one part of the pathway
When clinically feasible, neurosurgical tissue acquisition can provide diagnosis and may reduce tumor burden, but the operation must be integrated with postoperative pathology, imaging, radiation oncology and systemic treatment planning. If resection is not appropriate, a stereotactic biopsy may be considered to obtain diagnostic tissue. The exact neurosurgical approach depends on location, neurologic risk and treatment goals.
What records to send before travelling
A remote review is much more useful when the receiving neuro-oncology team can reconstruct the complete course.
- Preoperative and most recent brain MRI in original DICOM format
- Operative report and early postoperative MRI if surgery was performed
- Neuropathology report and molecular findings
- Information on IDH status and MGMT promoter methylation when available
- Radiotherapy plan, dose and treatment dates
- Systemic treatment history with dates and tolerance
- Current corticosteroid and anti-seizure medication
- Current neurologic symptoms and performance status
- Recent blood count, kidney and liver function when systemic treatment is being considered
Radiation and systemic treatment need multidisciplinary sequencing
Freiburg describes brain-tumor care that combines operative treatment with radiation oncology and medical oncology, while Heidelberg integrates neuro-oncology with radiotherapy, neuropathology and molecular diagnostics. Treatment should therefore be planned as a coordinated episode rather than by choosing a machine or drug in isolation.
Molecular markers can influence prognosis, treatment questions and trial eligibility
Heidelberg's program emphasizes molecular stratification and current trials include molecularly defined groups such as MGMT-unmethylated glioblastoma. Molecular results do not automatically determine one treatment, but they can materially affect interpretation of the disease and the relevance of research options.
Recurrence deserves a fresh multidisciplinary review
At progression, options can differ from first-line care and may include repeat surgery in selected patients, another systemic approach, re-irradiation in selected settings or a clinical trial. Heidelberg currently lists recruiting studies for first progression and progressive glioblastoma. Trial availability changes, so eligibility must be confirmed directly with the center.
Clinical trials are research options, not guaranteed treatment
Heidelberg currently lists recruiting glioblastoma studies, including GBM AGILE and studies for molecularly defined or recurrent disease. A trial listing does not mean that an international patient is eligible, that a study will remain open, or that research treatment is superior to standard care. Ask the center to assess eligibility from the complete record before arranging travel.
Plan neurologic support and follow-up before the return trip
Brain-tumor treatment can affect cognition, mobility, seizures and steroid requirements. Before returning home, clarify medication changes, seizure precautions, wound or radiation follow-up, the timing of the next MRI and which local neurologist, oncologist or neurosurgeon will manage urgent problems between German appointments.
Sources and review
This guide was last source-reviewed on 2026-08-30.